日本理化学研究所(RIKEN)先导研究中心的研究人员开发了一种新型抗癌策略,旨在通过“欺骗”机制让癌细胞自行生产杀死自身的药物 1。该研究由 Katsunori Tanaka 领导,其核心思路是利用癌细胞自然产生的过量一氧化碳作为原料,在肿瘤内部直接原位合成具有细胞毒性的菲啶酮衍生物 1。相关研究成果已于2026年11月3日发表在《Nature Communications》期刊上 1。
为了实现这一选择性毒性,团队采用白蛋白作为保护载体包裹钯环化合物催化剂,确保反应仅在特定环境下触发 1。实验数据显示,该技术具备高度的靶向性:在人类肝脏、宫颈、乳腺和肺癌的体外培养细胞系中成功检测到生成的菲啶酮,而在正常细胞中则未检出 1。此外,当该体系处于血液环境中时,血红蛋白会结合游离的一氧化碳,从而有效阻止药物在全身范围内提前生成,避免对健康组织造成损伤 1。尽管初步结果令人鼓舞,研究团队表示下一步计划将从细胞实验阶段推进至动物模型测试,以进一步验证该技术的安全性和有效性 1。
Scientists at the RIKEN Pioneering Research Institute (PRI) have developed a novel anti-cancer strategy that exploits carbon monoxide naturally produced by tumor cells to synthesize lethal drugs directly within cancerous tissue. Led by researcher Katsunori Tanaka, the team designed a system in which palladacycle precursors are protected by albumin carriers, ensuring that the catalytic reaction generating toxic phenanthridinone derivatives occurs selectively inside cancer cells while sparing healthy ones 1. The findings from this study were published in Nature Communications on November 3, 2026 1.
The mechanism relies on excess carbon monoxide generated by cancer cells as a raw material for in situ drug synthesis. Experimental results confirmed that phenanthridinone was detected in human liver, cervical, breast, and lung cancer cell lines but not in normal cells, demonstrating high selectivity 1. Furthermore, the study showed that no toxic drugs were produced in the blood because hemoglobin binds circulating carbon monoxide, effectively preventing premature activation of the therapy 1. While these initial tests were conducted on cultured cells, the research team plans to advance the technology to animal models in future studies 1.
评论
还没有评论,欢迎留下第一条。